P3231 - Does Obesity Affect Outcomes of LINX® Reflux Management System, Insights From the National Inpatient Sample

Mohamed Ahmed, MD¹, Khaled Elfert, MD², Islam Mohamed, MD³, Saqr Alsakarneh, MD³, Noor Mohamed, MD⁴, Noor Hassan, MD³, Fouad Jaber, MD³, Hassan Ghoz, MD^3
1University of Missouri Kansas City, Overland Park, KS; ²SBH Health System, Bronx, NY; ³University of Missouri-Kansas City, Kansas City, MO; ⁴Alexandria University, Alexandria, Al Iskandariyah, Egypt

Introduction: The LINX Reflux Management System is emerging as an alternative solution for treatment of gastroesophageal reflux disease (GERD). With obesity constituting a strong risk factor for GERD, its impact on this procedure remains understudied. The aim of this study is to assess outcomes of the LINX Reflux Management System in obese patients.

Methods: Patients hospitalized between 2016 and 2020 were admitted for the LINX Reflux Management System procedure. were identified using International Classification of Diseases Code,10^th Revision Clinical Modification (ICD-10) identified from the Healthcare Cost and Utilization Project databases (HCUP) using the National inpatient sample (NIS). Patients were further subclassified to BMI < 30 and >30 and their general characteristics and outcomes were compared.

Results: A total of 2095 procedures were identified. 280 (13.3%) patients had BMI 30 or above. There were no mortality rates in both groups. Length of stay (LOS) was similar in both groups (1.78 days, 95% CI 1.37-2.17 in the BMI >30 group vs 2.44 days, 95% CI 1.68-3.21 in the BMI < 30 group). Mean age was similar in both groups (56.98, 95% CI 53.8-60.12 vs 58.32, 95% CI 56.64-60.01). 69.94% of the BMI >30 group were females as compared to 64.46% in the other group. Most patients were white in both groups (87.5% vs 81.74%, p=0.445). Total charges were 90813.28 (95% CI 73700.18 - 107926.4) in the first group compared to 85054 (95% CI 71999.36 0 -98108.64) in the second group with p value of 0.58. Linear regression did not show statistical differences between both groups in LOS and total charges.

Discussion: The LINX Reflux Management System appears to be of equal efficacy and safety in patients with BMI > 30. It represents an alternative therapeutic option in patients with GERD. Further studies are needed to assess the long term outcomes and complications in this cohort.


Disclosures:


Mohamed Ahmed, MD¹, Khaled Elfert, MD², Islam Mohamed, MD³, Saqr Alsakarneh, MD³, Noor Mohamed, MD⁴, Noor Hassan, MD³, Fouad Jaber, MD³, Hassan Ghoz, MD³. P3231 - Does Obesity Affect Outcomes of LINX® Reflux Management System, Insights From the National Inpatient Sample, ACG 2023 Annual Scientific Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.